ArticleFrontiers in microbiology2026
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. The latest research shows that its pathogenesis is closely related to the imbalance of gut microbiota. Methods: PVP composition was characterized via UPLC-MS/MS and HPLC. Enzymatic kinetics, fluorescence quenching, and molecular docking were used to study the inhibition of PVP and rosmarinic acid (RA) on cholesterol esterase (CEase). Effects on liver lipid accumulation and intestinal cholesterol transport were assessed using HepG2 and Caco-2 cell models. A MASLD mouse model was evaluated through ELISA, tissue staining, and 16S rRNA sequencing to determine the efficacy and mechanisms. Results: PVP and RA exhibited anti-competitive inhibition of CEase, with IC Conclusion: PVP ameliorates MASLD by inhibiting CEase and intestinal cholesterol absorption, promoting cholesterol efflux, and regulating TBA levels along with intestinal microbiota homeostasis. Our findings suggest that PVP and RA deserve further investigation as potential modulators of cholesterol metabolism in MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.